lundi 15 juin 2020

Onco Actu du 15 juin 2020

Neutrophil ‘safety net’ causes cancer cells to metastasize and proliferate [Nature] 
Immune cells called neutrophils can support the spread of cancer. How neutrophils aid this process now comes into focus through insights into the function of structures called neutrophil extracellular traps.

The participants of the current study were identified carriers of Lynch Syndrome. The results were published in a distinguished medical journal The Lancet.

FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers [Merck] 
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Now Approved for the Prevention of HPV-Related Cervical, Vaginal, Vulvar, Anal, Oropharyngeal and Other Head and Neck Cancers.

FDA approves Gardasil 9, the HPV vaccine, to prevent head-and-neck cancer [STAT] 
The FDA is granting what’s known as an accelerated approval, meaning that the decision is contingent on the production of more data and is based on what’s known as a “surrogate endpoint” — an indication that a medicine works that is not foolproof. 

Thirty people with incurable cancer and chronic nausea enrolled in the new study. None had received chemotherapy or radiation therapy in the 2 weeks prior to enrolling, or antipsychotic medications in the 30 days prior to enrolling. 

Royal Marsden trial leads to practice changing milestone for advanced anal cancer [Royal Marsden] 
Published in the Journal of Clinical Oncology, researchers found that a chemotherapy combination of carboplatin and paclitaxel – which is primarily used to treat other cancers, including ovarian, womb and lung cancer - performed better overall with anal cancer patients living seven months longer compared to chemotherapy treatment with cisplatin and 5-fluorouracil.

Evidence for efficacy is based on the results from the RELAY study.

Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe [Gilead] 
Amsterdam Facility will Bring Kite’s Potentially Life-Saving Individualized Treatment Closer to People with Advanced Blood Cancers in the European Region.

GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track [Xconomy] 
The oncology R&D head explained that GSK’s cancer drug development strategy falls into four major categories, the first and largest of which is immuno-oncology – including belantamab mafodotin, dostarlimab, the inducible T-cell co-stimulator (ICOS) agonist GSK3359609 and several earlier clinical-stage candidates against TIM-3, LAG-3, OX40, STING and TLR4.

New Data Support Role of Agendia BluePrint Test in Refining Breast Cancer Subtypes [Genome Web] 
In poster presentations at the American Society of Clinical Oncology's virtual annual meeting earlier this month, investigators presented two new studies of BluePrint classification patterns. The company highlighted both as illustrating how the test's molecular classifications can reveal different information about a breast cancer's aggressiveness or responsiveness to treatment than would be gleaned from traditional factors like HER2 and ER biomarker status.

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020 [Roche] 
Phase III VIALE-A study showed Venclexta/Venclyxto plus azacitidine helped people with the most common type of aggressive adult leukaemia live longer compared to azacitidine alone.

EHA: AbbVie, Roche cement Venclexta's place in AML with survival win [Fierce Pharma] 
The trial win is key for AbbVie and Roche, as it backs up a conditional AML approval the FDA doled out in late 2018 based on response rates. 

Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™ (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy [Takeda] 
Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation.

Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting 
Selinexor Demonstrates a Significant Survival Benefit in Patients with Relapsed or Refractory DLBCL and Durable Responses in Important DLBCL Patient Subgroups, Including Those with Primary Refractory Disease and Regardless of Number of Prior Therapies.